Under the partnership, the custom technologies unit of Molecular Devices and the Discovery Technologies team at the Roche Innovation Center Basel of Pharma Research and Early Development (pRED) will develop a high-throughput detection system for drug discovery screens.
It will employ Roche’s Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF) assays.
The pRED screening teams in Basel and Shanghai are currently deploying the custom-developed Nano-TRF cartridge in their existing Molecular Devices SpectraMax Paradigm multimode microplate readers.
The teams will receive on-demand delivery of new cartridges and worldwide technical support.
Molecular Devices Global Services & Custom Solutions vice-president Shawn Laymon said: "We make the instruments that only existed as ideal specs in a team meeting or a protocol draft.
"We look forward to a continued relationship with Roche and to building new relationships with customers looking for a partner to help them create custom detection and analysis systems that meet their specific workflow needs."
Nano-TRF is a Ruthenium-based time-resolved assay utilized in high-throughput screening for drug discovery.
Molecular Devices’ SpectraMax Paradigm Multi-Mode Detection Platform features a cartridge-based system that expands the plate reader capability beyond traditional assays.
It will include applications like western blotting and imaging cytometry.
